Array BioPharma Inc. (NASDAQ:ARRY) and Allogene Therapeutics Inc. (NASDAQ:ALLO), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of the two firms.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Array BioPharma Inc.	180.09M	28.61	111.47M	-0.53	0.00
Allogene Therapeutics Inc.	N/A	0.00	211.50M	0.00	0.00

Table 1 highlights Array BioPharma Inc. and Allogene Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Array BioPharma Inc.	-61.90%	-45.1%	-22.4%
Allogene Therapeutics Inc.	0.00%	0%	0%

Liquidity

Array BioPharma Inc. has a Current Ratio of 6.3 and a Quick Ratio of 6.3. Competitively, Allogene Therapeutics Inc.’s Current Ratio is 1.6 and has 1.6 Quick Ratio. Array BioPharma Inc.’s better ability to pay short and long-term obligations than Allogene Therapeutics Inc.

Analyst Recommendations

In next table is given Array BioPharma Inc. and Allogene Therapeutics Inc.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Array BioPharma Inc.	0	1	4	2.80
Allogene Therapeutics Inc.	0	0	2	3.00

Array BioPharma Inc.’s upside potential currently stands at 8.01% and an $25.5 consensus price target. Allogene Therapeutics Inc. on the other hand boasts of a $45 consensus price target and a 70.97% potential upside. Based on the analysts opinion we can conclude, Allogene Therapeutics Inc. is looking more favorable than Array BioPharma Inc.

Insider and Institutional Ownership

Institutional investors held 0% of Array BioPharma Inc. shares and 52.3% of Allogene Therapeutics Inc. shares. Array BioPharma Inc.’s share held by insiders are 0.4%. Comparatively, Allogene Therapeutics Inc. has 21.2% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Array BioPharma Inc.	0.72%	26.73%	45.15%	53.84%	33.98%	66.04%
Allogene Therapeutics Inc.	0.66%	5.31%	4.72%	0%	0%	18.6%

For the past year Array BioPharma Inc. was more bullish than Allogene Therapeutics Inc.

Summary

On 6 of the 11 factors Allogene Therapeutics Inc. beats Array BioPharma Inc.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.